Multiple somatic aberrations in human cancer challenge our understanding of the mechanisms underlying cancer initiation, progression, and metastasis ([@r1], [@r2]). Alterations in secondary tumor drivers and modifiers can diversify signaling pathways, which modulate cancer cell fate as well as therapeutic efficacy. Human lung cancer is the leading cause of cancer-related mortality ([@r3]). Human lung cancer is classified into small cell lung cancer (∼15%) and non-small cell lung cancer (NSCLC; ∼85%). Lung squamous cell carcinoma (SCC; 25%) and adenocarcinoma (ADC; 65%) are the main types of NSCLC. Due to a decline in the smoking population, lung ADC has emerged as the predominant lung malignancy in humans. ADC is frequently located in the lower lobes of the lungs or peripheral lung tissues and is derived from type I and II lung epithelial cells ([@r4]). SCC is located in the upper lungs and is derived from the basal cells of the bronchial epithelium, and it specifically expresses keratin 5 (K5) and K14 basal cell markers ([@r5]). Understanding how these different cancer-associated genetic alterations regulate lung tumorigenesis is important for the design of rational treatments.

Human cancer genome sequencing identifies activating *KRAS* mutations in ∼35% of lung ADC and 5% of lung SCC, and mutations of the gene encoding Kelch-like ECH-associated protein 1 (KEAP1), an E3 ubiquitin ligase that induces degradation of nuclear factor (erythroid-derived 2)-like 2 (NRF2), in 18% and 12% of lung ADC and SCC, respectively ([@r1], [@r2]). *KEAP1* mutations can result in NRF2 accumulation and antioxidant responses ([@r6]). In addition, oncogenic Kras and Myc induce NRF2 expression, and the PI3K-AKT signaling activates NRF2 ([@r7]). The increased NRF2 exerts its oncogenic potential by enhancing AP-1 and Adam10/EGFR activities and protecting cancer cells from reactive oxygen species (ROS)-induced death ([@r8][@r9]--[@r10]).

The IκB kinase (IKK) complex, composed of IKKα, IKKβ, and NEMO (IKKγ), is essential for the activation of NF-κB and other important cellular functions ([@r11]). IKKα regulates canonical and noncanonical NF-κB signaling as well as NF-κB--independent functions ([@r12][@r13][@r14]--[@r15]). KEAP1 also regulates turnover of IKKβ, but not of IKKα or NEMO ([@r16]). NF-κB activity is required for Kras-initiated lung ADC development because it supports cell survival ([@r17]), and an absence of IKKβ attenuates Kras-induced ADC development ([@r18]). We have previously shown that lung IKKα inactivation induces spontaneous SCC development in mice, associated with increased lung inflammation ([@r5]); however, the role of IKKα in lung ADC is unclear.

ROS are essential for maintaining cellular metabolism, survival, proliferation, and differentiation in normal cells. Cancer cells adapt to exist with elevated ROS levels compared with normal cells ([@r19], [@r20]). Numerous studies have documented that excessive ROS either promote tumor development or kill cancer cells via an apoptotic mechanism ([@r21], [@r22]). In response to ROS, NRF2 up-regulates the expression of antioxidants and detoxifying enzymes, thereby maintaining ROS homeostasis. NRF2 has been shown to inhibit Kras^G12D^-initiated early lung ADC but to accelerate advanced ADC ([@r23]); however, most human lung ADCs do not harbor *KEAP1* mutations that result in NRF2 accumulation ([@r1], [@r24]). Thus, there remains a need to identify additional NRF2 regulators and mechanisms underlying NRF2 accumulation or down-regulation in lung ADC.

Chemical carcinogens induce activating *Hras* mutations and ROS accumulation in mouse skin ([@r25], [@r26]). Deletion of NRF2 or NAD(P)H quinone dehydrogenase 1 (NQO1, an NRF2 target) enhances carcinogen-induced skin carcinogenesis in mice ([@r27], [@r28]). *Ikka*^*+/−*^ mice develop many more skin papillomas and malignant carcinomas than wild-type (WT) mice in response to carcinogen administration ([@r26]). Given the known activities of NRF2 and NQO1 in scavenging ROS, these phenotypic similarities among NRF2, NQO1, and IKKα suggest that all may impact ROS accumulation and Hras activation during skin tumorigenesis. To date, the regulatory relationship between NRF2 and IKKα remains unclear. Moreover, activated Kras promotes ROS accumulation, which induces cell senescence ([@r29][@r30]--[@r31]), antagonizing Kras-initiated lung ADC progression. How NRF2 regulates the antitumorigenic effects of Kras-induced ROS merits further investigation.

The Cancer Genome Atlas (TCGA) database analysis has revealed the mutations and deletions in the *CHUK* locus, which encodes IKKα, in a subfraction of human lung ADC. Here we show that lung-specific IKKα ablation induces spontaneous lung ADC and promotes Kras-initiated lung ADC development in mice, and further demonstrate that IKKα controls ADC development through its unique effects on ROS metabolism, mediated through NRF2 and NOX2.

Results {#s1}
=======

Lung Epithelial Cell IKKα Suppresses ADC Development. {#s2}
-----------------------------------------------------

To investigate the effect of IKKα on lung ADC development, we ablated IKKα in lungs of C57BL/6 *Ikkα*^*f/f*^ mice ([@r15]) by intratracheal Adenovirus.Cre (Ad.Cre) administration (*Ikkα*^∆*Lu*^). Conditional deletion of IKKα resulted in spontaneous lung ADCs in 8 out of 48 *Ikkα*^∆*Lu*^ mice at 13--20 mo of age ([Fig. 1*A*](#fig01){ref-type="fig"}, *Top*). No lung ADCs were detected in 30 WT mice. Activating *KRAS* mutations at amino acid 12 are commonly identified in human lung ADC ([@r1]), and Kras^G12D^ activation induces spontaneous lung ADC in mice ([@r32]). Thus, ADC developed from C57BL/6 *Kras*^*LSL-G12D*^ (*Kras*^*G12D*^) mice were used as positive controls ([Fig. 1*A*](#fig01){ref-type="fig"}, *Bottom*). With increasing age, ADC derived from *Ikkα*^∆*Lu*^ mice metastasized to the spleen and other organs, as indicated by positivity for SP-C, a marker of type II lung epithelial cells ([Fig. S1*A*](#d35e591){ref-type="supplementary-material"}).

![IKKα deletion induces spontaneous lung ADCs and promotes Kras-initiated lung ADCs, and somatic *CHUK* aberrations are detected in human lung ADCs. (*A*, *Top*) Lung-specific IKKα ablation by intratracheal Ad.Cre injection induced spontaneous lung ADCs in 8 of 48 *Ikkα*^∆*Lu*^ mice and in 0 of 30 WT mice. ADCs stained with hematoxylin and eosin (H&E) in *Ikkα*^∆*Lu*^ mice at age 13 mo. (*A*, *Bottom*) H&E-stained ADCs from *Kras*^*G12D*^ mice served as a positive control. (Scale bar: 30 μm.) All images in this study were captured by a Nikon (Ver. 3.06) microscope. (*B*) Lung ADC burden in *Kras*^*G12D*^ and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice at 4 mo after Ad.Cre treatment (*n* = 6 mice/group) and a representative H&E-stained ADC. \*\*\**P* \< 0.001, Student's *t* test. (Scale bar: 25 μm.) (*C*) Lung ADC burden in *Kras*^*G12D*^ and *Kras*^*G12D*^*;Ikkα*^*KA/KA*^ mice at 4.5 mo after Ad.Cre treatment (*n* = 4 mice/group) and a representative H&E-stained ADC. \*\**P* \< 0.01, Student's *t* test. (Scale bar: 25 μm.) (*D*) Immunofluorescence (IF) staining with anti--SP-C or anti--CC10 antibody showing the tissue origins of ADCs in *Kras*^*G12D*^*, Kras*^*G12D*^*;Ikkα*^∆*Lu*^, and *Kras*^*G12D*^*;Ikkα*^*KA/KA*^ mice and WT lungs (*n* = 3 mice/group). DAPI, nuclear staining. (Scale bar: 30 μm.) (*E*) ADCs from *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice were stained by immunohistochemistry (IHC) with K5 or SP-C antibody (*n* = 3). (Scale bar: 30 μm.) (*F*) Survival of *Kras*^*G12D*^ mice compared with several IKKα mutants crossed with *Kras*^*G12D*^ mice. \*\**P* \< 0.01; \**P* \< 0.05, Mantel--Cox log-rank test. Mouse numbers and *P* values are shown. The red asterisk indicates IKKα reduction; the red ^\#^, LOH. (*G*, *Top*) *CHUK* mutations and deletion were found in 230 human lung ADCs (cBioPortal for Cancer Genomics) ([@r1]) that generate truncated IKKα proteins labeled with red numbers. aa, amino acid; HLH, helix-loop-helix; KD, kinase domain; LZ, leucine zipper. (*G*, *Bottom*) Analysis of CHUK (IKKα) mRNA expression (RNA sequence V2 RSEM) in 230 human lung ADCs ([@r1]). Putative copy number calls on 230 cases were determined using GISTIC 2.0. Values: −2, homozygous deletion; −1, hemizygous (shallow) deletion; 0, neutral/no change; 1, gain; 2, high-level amplification. (*H*) Survival curves for patients with *CHUK* alterations, including mutations (M) and hemizygous deletions (Hem), *KRAS* mutations, and *KRAS* mutations/*CHUK* hemizygous deletions. \*\**P* \< 0.01, χ^2^ test (comparisons between two groups).](pnas.1717520115fig01){#fig01}

To investigate the effect of IKKα on Kras^G12D^-induced lung ADC, we crossed C57BL/6 *Ikkα*^*f/f*^ mice or *Ikkα*^*KA/KA*^ mice with C57BL/6 *Kras*^*G12D*^ mice and used Ad.Cre to induce Kras^G12D^ expression and simultaneously delete IKKα. *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ and *Kras*^*G12D*^*;Ikka*^*KA/KA*^ mice showed a significantly greater lung tumor burden compared with *Kras*^*G12D*^ mice ([Fig. 1 *B* and *C*](#fig01){ref-type="fig"} and [Fig. S1*B*](#d35e591){ref-type="supplementary-material"}). ADCs derived from *Kras*^*G12D*^, *Kras*^*G12D*^*;Ikkα*^∆*Lu*^, and *Kras*^*G12D*^*;Ikkα*^*KA/KA*^ mice were positive for SP-C and CC10 (a marker of lung epithelial Clara cells), but negative for K5, an SCC marker ([Fig. 1 *D* and *E*](#fig01){ref-type="fig"}). We confirmed *Ikkα* deletion and *Kras*^*G12D*^ activation in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lung ADCs and *Kras*^*G12D*^ activation in *Kras*^*G12D*^*;Ikka*^*KA/KA*^ ADCs ([Fig. S1*C*](#d35e591){ref-type="supplementary-material"}).

Following Ad.Cre treatment, *Kras*^*G12D*^*;Ikkα*^*f/f*^, *Kras*^*G12D*^*;Ikkα*^*f/+*^, and *Kras*^*G12D*^*;Ikkα*^*+/−*^ mice showed a significantly reduced life span compared with *Kras*^*G12D*^ mice ([Fig. 1*F*](#fig01){ref-type="fig"} and [Fig. S1*D*](#d35e591){ref-type="supplementary-material"}). Loss of the WT *Ikkα* allele \[i.e., loss of heterozygosity (LOH), a tumor- suppressor hallmark\] was detected in *Kras*^*G12D*^*;Ikkα*^*+/−*^ lung ADCs ([Fig. S1*E*](#d35e591){ref-type="supplementary-material"}). *Ikkα* LOH was previously reported in carcinogen-induced skin tumors in *Ikkα*^*+/−*^ mice ([@r26]). Collectively, these results indicate that lung epithelial cell IKKα ablation promotes Kras^G12D^-initiated lung ADC development. Although FVB [*l*]{.smallcaps}*-Ikkα*^*KA/KA*^ mice, in which lysine is replaced by alanine at amino acid 44 of IKKα, develop spontaneous lung SCC ([@r5]), we did not detect lung SCC in FVB or C57BL/6 *Ikkα*^∆*Lu*^ mice, *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice, or *Kras*^*G12D*^*;Ikka*^*KA/KA*^ mice in this study.

We then examined the TCGA database (cBioPortal) of Human Cancer Genomics ([@r1]) and found a 2.2% mutation rate in the *CHUK* locus in lung ADC, including *CHUK*^*X411*^ and *CHUK*^*E53*^ point mutations, which generate the C-terminal truncated IKKα variants lacking its leucine zipper (LZ) and helix-loop-helix (HLH) domains, as well as *CHUK* homozygous deletions ([Fig. 1*G*](#fig01){ref-type="fig"}, *Top*). We also found *CHUK* hemizygous deletions in ∼22% of human lung ADCs ([Fig. 1*G*](#fig01){ref-type="fig"}, *Bottom*). The LZ and HLH motifs are required for IKKα activity ([@r13], [@r15], [@r33], [@r34]). Human lung ADCs carrying *CHUK* mutations had an activating *KRAS* mutation that causes an amino acid change at position 12, as well as *TP53* mutations ([Fig. 1*G*](#fig01){ref-type="fig"}, *Top* and [Fig. S1*F*](#d35e591){ref-type="supplementary-material"}). Eight out of 51 human lung ADCs bearing a *CHUK* hemizygous deletion also had an activating *KRAS* G12C or G12V mutation ([Fig. 1*G*](#fig01){ref-type="fig"}, *Bottom*), suggesting that some *CHUK* alterations have a positive correlation with activating *KRAS* mutations.

We also examined the effect of *CHUK* mutations on the survival of patients with lung ADC. The median survival of the patients in this cohort is 44.6 mo ([@r1]), compared with 19.5 mo for patients with *CHUK* mutations and 35.5 mo for patients with *KRAS* mutations. Although the number of patients with a *CHUK* mutation is limited, the data suggest that patients with lung ADC with *CHUK* mutations may have a tendency toward shorter survival. We further compared the survival curves among patients with *CHUK* alterations, including mutations and hemizygous deletions, *KRAS* mutations, and *KRAS* mutations/*CHUK* hemizygous deletions, and found that *CHUK* mutations or hemizygous deletions significantly reduced the survival time of patients with lung ADC carrying a *KRAS* mutation ([Fig. 1*H*](#fig01){ref-type="fig"}). Based on the foregoing animal results, IKKα inactivation may promote human lung ADC development.

Reduced IKKα Promotes Bronchial Epithelial Cell Proliferation and Attenuates Cell Senescence. {#s3}
---------------------------------------------------------------------------------------------

Compared with *Kras*^*G12D*^ mice, *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ and *Kras*^*G12D*^*;Ikka*^*KA/KA*^ mice developed significantly enlarged lungs with markedly increased Ki67-positive bronchial epithelial cells, which can give rise to lung ADCs ([Fig. 2 *A* and *B*](#fig02){ref-type="fig"} and [Fig. S2*A*](#d35e591){ref-type="supplementary-material"}), suggesting that IKKα reduction or deletion promotes lung epithelial cell proliferation. The *Ikkα*^*KA*^ mutation severely destabilizes IKKα and also abolishes its catalytic activity ([@r5]). Indeed, IKKα levels were decreased in *Kras*^*G12D*^*;Ikka*^*KA/KA*^ lung ADCs compared with WT lungs and *Kras*^*G12D*^ ADCs ([Fig. S2*B*](#d35e591){ref-type="supplementary-material"}). Moreover, following intratracheal treatment with Ad.Cre, a small group of *Kras*^*G12D*^*;Ikka*^*KA/KA*^ mice developed severe skin lesions, precluding their maintenance. Thus, we used *Ikka*^*f/f*^ mice for all subsequent studies.

![IKKα deletion promotes cell growth but reduces cell senescence. (*A*) Lung appearance and weights of *Kras*^*G12D*^ mice (*n* = 8) and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice (*n* = 7) and Ki67-stained bronchial epithelial cells in the lungs of these mice (*n* = 3 mice for 10 slides/group; *Right*) at 4 mo after Ad.Cre treatment. \*\**P* \< 0.01; \*\*\**P* \< 0.001, Student's *t* test. (*B*) Lung appearance and weight in four *Kras*^*G12D*^ and three *Kras*^*G12D*^*;Ikkα*^*KA/KA*^ mice (*Left* and *Center*) and Ki67-stained bronchial epithelial cells in the lungs of these mice (*n* = 3 mice/group; *Right*) at 4.5 mo after Ad.Cre treatment. \*\**P* \< 0.01, Student's *t* test. (*C*) Comparison of SA-β-gal staining intensities between *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ and *Kras*^*G12D*^ tumors (*n* = 3 mice/group). SA, senescence-associated. \*\**P* \< 0.01, Fisher's exact test. (*D*) IB analysis of IKKα, p53, and p21 expression in WT lungs and *Kras*^*G12D*^ and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs. β-actin served as a protein-loading control. (*E*) A scheme for generating Kras-CL and Kras^IKKαL^ cell lines involving intratracheal injections of these cells into WT mice with a C57BL/6 background. ADCs generated by these cells are stained with H&E. (Scale bar: 25 μm.) (*F*) IB analysis of IKKα in Kras-CL and Kras^IKKαL^ cells. β-actin served as a protein-loading control (*Top Left*). Shown are lung appearance (*Bottom Left*) and tumor burden (*Right*) in WT mice receiving intratracheal injections of Kras-CL (*n* = 4) or Kras^IKKαL^ (*n* = 5) cells (5 × 10^6^ cells/mouse), as analyzed statistically using Student's *t* test. \*\*\**P* \< 0.001. (*G*) The growth of tumors in nude mice receiving s.c. injection of IKKα- or control vector-transfected Kras^IKKαL^ cells (*n* = 5 mice/group) for 2 wk. Data represent mean ± SD. \*\**P* \< 0.01, Student's *t* test.](pnas.1717520115fig02){#fig02}

Oncogenic Kras^G12D^ induces premalignant lesions by increasing cell senescence, as indicated by senescence-associated β-galactosidase (SA-β-gal) staining ([@r30]). *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lung ADCs displayed substantially less SA-β-gal staining and more Ki67 than *Kras*^*G12D*^ ADCs ([Fig. 2*C*](#fig02){ref-type="fig"} and [Fig. S2*C*](#d35e591){ref-type="supplementary-material"}). The tumor suppressor p53 is essential for induction of cell senescence ([@r30]). Decreased p53 and p21^Cip1^ (p21) expression can overcome cell cycle arrest and senescence and thereby promote tumor progression. Immunoblot (IB) analysis showed lower expression of p53 and p21 in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ tumors than in *Kras*^*G12D*^ tumors ([Fig. 2*D*](#fig02){ref-type="fig"}), which may account for the hyperproliferative phenotype in the lungs of *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice compared with *Kras*^*G12D*^ mice. Of note, decreased IKKα expression was seen in some Kras^G12D^-lung ADCs and this was accompanied by reduced p53 and p21 expression ([Fig. 2*D*](#fig02){ref-type="fig"}). These results suggest that reduced IKKα expression in lung ADCs is associated with increased cell proliferation and decreased cell senescence.

To determine the epithelial cell-autonomous role of IKKα in lung ADC development, we generated a *Kras*^*G12D*^ ADC (Kras-CL) cell line ([Fig. 2*E*](#fig02){ref-type="fig"}) and transplanted these cells into the lungs of C57BL/6 WT mice. From the resulting lung ADCs, we isolated another cell line, Kras^IKKαL^, that expressed less IKKα than the parental Kras-CL cells ([Fig. 2*E*](#fig02){ref-type="fig"} and [Fig. 2*F*](#fig02){ref-type="fig"}, *Top Left*). Kras^IKKαL^ cells generated many more ADCs than the parental Kras-CL cells after transplantation into C57BL/6 WT mice, although both cell lines contained an activated Kras^G12D^ allele ([Fig. 2*F*](#fig02){ref-type="fig"}, *Bottom Left* and *Right* and [Fig. S2*D*](#d35e591){ref-type="supplementary-material"}). To verify the inhibitory effect of IKKα on tumorigenesis, we reexpressed IKKα into Kras^IKKαL^ cells and found that reintroduction of IKKα reduced tumor sizes compared with controls when these cells were injected s.c. into nude mice ([Fig. 2*G*](#fig02){ref-type="fig"} and [Fig. S2*E*](#d35e591){ref-type="supplementary-material"}). These results indicate that reduced IKKα expression in lung ADC cells promotes tumorigenesis.

IKKα Ablation Enhances ROS in Lung ADCs, and Treatment with Apocynin Attenuates ROS and Lung Tumorigenesis. {#s4}
-----------------------------------------------------------------------------------------------------------

ROS induce p53 expression ([@r35]). Unexpectedly, however, we detected more ROS in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs than in *Kras*^*G12D*^ ADCs ([Fig. 3*A*](#fig03){ref-type="fig"}). Using gene expression array analysis (GSE84159), we found increased expression of genes encoding the NADPH oxidase (NOX) complex subunits that are involved in ROS generation ([@r36]), such as Cyba, Ncf2, Ncf1, and Cybb, which encodes NOX2 ([@r37]), in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs compared with *Kras*^*G12D*^ lungs ([Fig. 3*B*](#fig03){ref-type="fig"}). We did not observe increased expression of other NOX types. RT-PCR confirmed the significantly higher levels of Nox2 in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs compared with *Kras*^*G12D*^ lungs ([Fig. 3*C*](#fig03){ref-type="fig"}). Moreover, IB analysis showed significantly higher NOX2 levels in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs compared with *Kras*^*G12D*^ ADCs ([Fig. 3*D*](#fig03){ref-type="fig"} and [Fig. S3*A*](#d35e591){ref-type="supplementary-material"}). Indeed, some human lung ADCs expressed reduced IKKα and increased NOX2 ([Fig. 3*E*](#fig03){ref-type="fig"}). Another analysis ([@r1]) showed a negative correlation between NOX2 and IKKα expression in human lung ADCs ([Fig. S3*B*](#d35e591){ref-type="supplementary-material"}), suggesting the relevance of reduced IKKα and increased NOX2 in human lung ADC development.

![IKKα ablation increases NOX2 expression, and NOX inhibition reduces lung tumor burden. (*A*) Increased levels of ROS stained with IF (*Left*) for 2′,7′-dichlorofluorescein diacetate (DCF-DA, in green) in tumors derived from *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice compared with *Kras*^*G12D*^ tumors and WT lungs (*Right*). *n* = 6/group. \*\*\**P* \< 0.001, Student's *t* test. (*B*) Comparison of expression levels of genes encoding Cyba, Ncf2, Ncf1, and Cybb in *Kras*^*G12D*^*;Ikkα*^Δ*Lu*^ lungs vs. WT (red) and in *Kras*^*G12D*^ lungs vs. WT (green), as determined by gene array analysis. Red asterisk: Cybb is also the name of the Nox2 gene. (*C*) RT-PCR analysis of Nox2 mRNA expression in *Kras*^*G12D*^ and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs (*n* = 6). Data represent mean ± SEM (three repeats). \**P* \< 0.05, Student's *t* test. (*D*) IB analysis of NOX2 expression in four *Kras*^*G12D*^ and five *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lung ADCs ([Fig. S3*A*](#d35e591){ref-type="supplementary-material"}). Data represent mean ± SD (three repeats). \**P* \< 0.05, Student's *t* test. (*E*) IB analysis of IKKα, NOX2, and NRF2 expression in human lung ADCs. Red asterisks indicate a relationship between IKKα and NOX2. β-actin served as a protein-loading control. (*F* and *G*) Apocynin (100 μM) or NAC (10 mM) reduces ROS (stained with DCF-DA) induced by IKKα down-regulation in human A549 cells (*F*) and mouse Kras-CL cells (*G*). (*H*) The effect of apocynin on lung tumor burden in *Kras*^*G12D*^ (*Right*) and *Kras*^*G12D*^*;Ikkα*^Δ*Lu*^ (*Left*) mice. *n* = 6 for untreated mice; *n* = 9 for treated mice). \**P* \< 0.05, Student's *t* test. n.s., not significant.](pnas.1717520115fig03){#fig03}

To verify whether IKKα expression is inversely correlated with ROS in lung ADC, we knocked down IKKα in human A549 lung ADC cells, which carry a *Kras*^*G12S*^ mutation ([@r38]), and in mouse Kras-CL ADC cells. Down-regulation of IKKα increased ROS in both A549 and Kras-CL cells, but treatment with apocynin, a NOX inhibitor ([@r36]), or *N*-acetyl cysteine (NAC), an antioxidant ([@r29]), decreased ROS accumulation in IKKα-deficient A549 and Kras-CL cells ([Fig. 3 *F* and *G*](#fig03){ref-type="fig"} and [Fig. S3 *C* and *D*](#d35e591){ref-type="supplementary-material"}). Oral administration of apocynin, dissolved in drinking water containing 1.5% ethanol, for 4 mo significantly reduced the lung ADC burden in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice compared with vehicle-treated *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice ([Fig. 3*H*](#fig03){ref-type="fig"}, *Left*); however, treatment with apocynin did not decrease the lung ADC burden in *Kras*^*G12D*^ mice compared with controls ([Fig. 3*H*](#fig03){ref-type="fig"}, *Right*). These results suggest that IKKα reduction results in increased amounts of NOX2 and intratumoral ROS. IKKα is part of the IKK complex, but knockdown of IKKα did not alter NF-κB activity in A549 cells ([Fig. S3*E*](#d35e591){ref-type="supplementary-material"}), suggesting that IKKα may regulate NOX2 expression and ROS levels via an NF-κB--independent mechanism.

Knockdown of NOX2 in Lung ADC Cells Inhibits Lung ADC Growth, and IKKα Regulates NOX2 Expression via the *Nox2* Promoter. {#s5}
-------------------------------------------------------------------------------------------------------------------------

To verify the relationships among epithelial cell IKKα, NOX2, and ROS in lung tumorigenesis, we confirmed higher ROS levels in Kras^IKKαL^ cells than in Kras-CL cells and verified that treatment with apocynin reduced ROS levels in Kras^IKKαL^ cells ([Fig. 4 *A* and *B*](#fig04){ref-type="fig"}). Because Kras-CL cells required more than 3 mo to generate lung ADCs in WT mice, we used Kras^IKKαL^ cells to determine the effect of NOX2 and ROS on ADC formation. Consistently, a 6-wk course of treatment with apocynin reduced Kras^IKKαL^ cell--generated lung ADC numbers and lung weights in C56BL/6 WT mice compared with controls ([Fig. 4*C*](#fig04){ref-type="fig"}). These results demonstrate that IKKα levels in lung ADC cells are inversely correlated with ROS levels and lung tumor development and that increased ROS enhance the tumorigenic potential of Kras^IKKαL^ cells.

![IKKα represses expression of Nox2 through regulation of AhR activity. (*A*, *Left*) DCF-DA staining for ROS in Kras-CL (Kras) and Kras^IKKαL^ (Kras^IKKαlow^) cells using flow cytometry. (*A*, *Right*) Relative DCF levels in the two cell lines (*n* = 4/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*B*) Treatment with apocynin (100 μM) reduces ROS in Kras^IKKαL^ cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*C*) Treatment with apocynin inhibits Kras^IKKαL^ cell-derived lung ADCs and reduces lung size in WT mice compared with the untreated control group. Experimental mice, *n* = 5; control mice, *n* = 6. \**P* \< 0.05; \*\**P* \< 0.01, Student's *t* test. (*D*) RT-PCR analysis of Nox2 mRNA expression in Kras-CL and Kras^IKKαL^ cells (*n* = 3). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*E*) DCF-DA levels of Kras^IKKαL^ cells treated with Si-control (control) or Si-Nox2. *n* = 3/group. Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*F*) Tumor appearance (*Left*) and numbers (*Right*) generated by Kras^IKKαL^ cell receiving Si-control and Si-Nox2 RNA in the lungs of WT mice. *n* = 5 for controls; *n* = 6 for Si-Nox2). Data represent mean ± SD \*\**P* \< 0.01; Student's *t* test. (*G*) ChIP analyses for IKKα and AhR binding to *Nox2* promoter using antibody against AhR (*Left*) or IKKα (*Right*) for IP, followed by PCR with *Nox2* promoter primers in Kras-CL cells (Si-Cont, control) or Kras-CL cells silencing IKKα or overexpressing WT IKKα, IKKα mutant lacking its LZ motif (IKKα-∆LZ), and IKKα-KA (kinase inactivation). Si-Cont, Si-control RNA; Si-IKKα, Si-IKKα RNA. Data represent mean ± SD (three repeats). \**P* \< 0.05; \*\*\**P* \< 0.001, Student's *t* test. n.s., not significant. (*H*) Knockdown of IKKα (Si-IKKα) or reintroduction of WT IKKα, IKKα-∆LZ, and IKKα-KA regulates Nox2 expression in Kras-CL cells, as analyzed by RT-PCR. Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001; \*\**P* \< 0.01, Student's *t* test. n.s., not significant. (*I*) A working model for regulation of Nox2 expression by IKKα through AhR. XRE, xenobiotic response element, a DNA-binding site for AhR on the *Nox2* promoter. IKKα deletion reduces AhR binding to the *Nox2* promoter, enhancing *Nox2* promoter activity and lung tumor development.](pnas.1717520115fig04){#fig04}

Furthermore, Kras^IKKαL^ cells expressed higher levels of Nox2 mRNA compared with Kras-CL cells ([Fig. 4*D*](#fig04){ref-type="fig"}), and silencing IKKα resulted in elevated NOX2 expression in A549 cells ([Fig. S4 *A* and *B*](#d35e591){ref-type="supplementary-material"}). In contrast, knockdown of NOX2 significantly attenuated ROS levels in Kras^IKKαL^ cells and impaired Kras^IKKαL^ cell-generated lung tumors in C57BL/6 WT mice at 6 wk after the transplantation of Nox2 Si-RNA-- or control Si-RNA--treated Kras^IKKαL^ cells ([Fig. 4 *E* and *F*](#fig04){ref-type="fig"}), although NOX2 knockdown had less effect on lung weight than apocynin, suggesting that increased NOX2 expression enhances the tumorigenic potential of Kras^IKKαL^ cells by elevating ROS levels.

We then investigated the mechanism underlying the regulation of NOX2 expression by IKKα. The aryl hydrocarbon receptor (AhR) is known to repress *Nox2* transcription ([@r39]). We postulated that IKKα may regulate *Nox2* transcription via its effects on AhR activity. Indeed, an interaction between IKKα and AhR was detected by pull-down assays with an anti-AhR or an anti-IKKα antibody in A549 cells ([Fig. S4*C*](#d35e591){ref-type="supplementary-material"}). In addition, kinase-inactive IKKα (IKKα-KA), but not a mutant IKKα with its LZ deletion from amino acids 441--531 (IKKα-∆LZ), interacted with AhR ([Fig. S4*D*](#d35e591){ref-type="supplementary-material"}), suggesting that IKKα may regulate Nox2 expression independent of its kinase activity. Chromatin immunoprecipitation (ChIP) assays demonstrated that both IKKα and AhR were associated with the xenobiotic response element-containing region of the *Nox2* promoter in Kras-CL cells and in human A549 cells ([Fig. 4*G*](#fig04){ref-type="fig"} and [Fig. S4 *E* and *F*](#d35e591){ref-type="supplementary-material"}). In contrast, IKKα depletion decreased the recruitment of AhR to the *Nox2* promoter, and reintroduction of WT IKKα or IKKα-KA, but not of IKKα-∆LZ, recruited AhR to the *Nox2* promoter in IKKα-deficient Kras-CL and A549 cells ([Fig. 4*G*](#fig04){ref-type="fig"} and [Fig. S4*E*](#d35e591){ref-type="supplementary-material"}, *Left*, and [Fig. S4*F*](#d35e591){ref-type="supplementary-material"}). Furthermore, silencing IKKα elevated Nox2 expression in Kras-CL cells, while reintroducing IKKα or IKKα-KA, but not IKKα-∆LZ, elevated NOX2 expression in IKKα-deficient Kras-CL cells ([Fig. 4*H*](#fig04){ref-type="fig"} and [Fig. S4*E*](#d35e591){ref-type="supplementary-material"}, *Right*), although a slight reduction in IKKα-KA binding to the *Nox2* promoter was seen, suggesting that IKKα integrity, but not its kinase activity, is required for the regulation of NOX2 expression. These results indicate that IKKα suppresses NOX2 expression by recruiting AhR to the *Nox2* promoter, whereas IKKα deletion diminishes AhR binding to the *Nox2* promoter, leading to increased Nox2 expression and ROS production ([Fig. 4*I*](#fig04){ref-type="fig"}).

*Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs Express Reduced NRF2, and NAC Treatment Inhibits Lung ADC Burden in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ Mice. {#s6}
----------------------------------------------------------------------------------------------------------------------------------------

A feedback loop between ROS production and elimination balances physiological ROS amounts. We expected to find that increased ROS resulted in NRF2 activation. Surprisingly, however, the expression of NRF2 target genes encoding antioxidants and detoxifying enzymes was lower in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs than in *Kras*^*G12D*^ lungs ([Fig. S5*A*](#d35e591){ref-type="supplementary-material"}). IB analysis showed that *Kras*^*G12D*^ ADCs expressed more NRF2 than WT lungs, whereas *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs expressed less NRF2 than WT lungs ([Fig. 5*A*](#fig05){ref-type="fig"}). Among *Kras*^*G12D*^ ADCs, those expressing less IKKα consistently showed lower NRF2 and p21 expression ([Fig. 5*B*](#fig05){ref-type="fig"}). Importantly, IB analysis showed reduced IKKα and NRF2 expression in a subfraction of human lung ADCs, and indeed, some human lung ADCs showed reduced IKKα and NRF2 expression and increased NOX2 expression ([Fig. 3*E*](#fig03){ref-type="fig"} and [Fig. S5*B*](#d35e591){ref-type="supplementary-material"}). Moreover, using RT-PCR, we examined additional 47 human lung ADCs (stage II--IV) and found that a subgroup of these ADCs expressed significantly less IKKα and NRF2 compared with another ADC group ([Fig. 5*C*](#fig05){ref-type="fig"}), suggesting clinical relevance of the reduced IKKα and NRF2 expression in human lung ADC.

![IKKα ablation reduces NRF2 expression, and inhibition of ROS decreases lung tumorigenesis. (*A*) IB analysis of NRF2 expression in WT lungs and *Kras*^*G12D*^ and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs. β-actin served as a protein-loading control. The same protein membrane was used as shown in [Fig. 2*D*](#fig02){ref-type="fig"}. (*B*) IB analysis of expression of IKKα, NRF2, and p21 in *Kras*^*G12D*^ ADCs. Based on expression levels of IKKα, these ADCs were divided into two groups: low group (*n* = 5) and high group (*n* = 9). NRF2 and p21 levels were further compared between the two ADC groups and then statistically analyzed using Student's *t* test. \**P* \< 0.05. (*C*) RT-PCR analysis of expression levels of IKKα/CHUK and NRF2 in 47 human lung ADCs. These ADCs were divided into two groups (*n* = 21 and *n* = 26) based on IKKα levels. Gapdh levels were used to normalize IKKα and NRF2 expression. \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001, Student's *t* test. (*D*) Lung weight and appearance in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice treated with (*n* = 5) or without (*n* = 4) NAC, statistically analyzed by Student's *t* test. \**P* \< 0.05. (*E*) Tumor burden in *Kras*^*G12D*^ mice (*Left*) treated with (*n* = 4) or without (*n* = 4) NAC and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice (*Right*) treated with (*n* = 5) or without (*n* = 4) NAC. Data were statistically analyzed by Student's *t* test. n.s., not significant. \*\*\**P* \< 0.001. (*F*) Oxidative DNA damage indicated by IF staining with 8-hydroxy-2′-deoxyguanosine (8-OHdG) in WT lungs and ADCs of *Kras*^*G12D*^, *Kras*^*G12D*^*;Ikkα*^∆*Lu*^, and NAC-treated *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice (*n* = 5). (Scale bar: 25 μm.) (*G*) RT-PCR analysis of Nqo1 and Gpx2 mRNA in *Kras*^*G12D*^ (*n* = 3) and *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ (*n* = 4) lung ADCs. Data were statistically analyzed by Student's *t* test. \*\**P* \< 0.01; \*\*\**P* \< 0.001.](pnas.1717520115fig05){#fig05}

If reduced NRF2 expression promotes ROS accumulation, which further contributes to increased tumorigenesis, then treatment with NAC should inhibit lung ADC burden in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice. Indeed, NAC treatment significantly decreased lung weights and ADC burden in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ mice compared with controls, but this treatment did not significantly affect the ADC burden in *Kras*^*G12D*^ mice ([Fig. 5 *D* and *E*](#fig05){ref-type="fig"}). The oxidative DNA damage (8-OHdG) marker was higher in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs than in *Kras*^*G12D*^ ADCs, and NAC treatment decreased DNA damage ([Fig. 5*F*](#fig05){ref-type="fig"}), suggesting that accumulated ROS cause more DNA damage, which is associated with enhanced lung tumorigenesis. As expected, the expression levels of NRF2 targets Nqo1 and Gpx2 were significantly lower in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ ADCs than in *Kras*^*G12D*^ ADCs ([Fig. 5*G*](#fig05){ref-type="fig"}), suggesting that ROS scavengers regulate lung ADC development in the absence of IKKα.

IKKα Loss Down-Regulates NRF2 Expression in an Epigenetic Manner. {#s7}
-----------------------------------------------------------------

Treatment with NAC decreased the number of ROS in Kras^IKKαL^ cells and also inhibited Kras^IKKαL^ cell-generated lung tumor growth in WT mice compared with controls ([Fig. 6 *A* and *B*](#fig06){ref-type="fig"}), suggesting a reciprocal correlation between IKKα-regulated NRF2 expression and ROS levels during lung tumorigenesis. KEAP1 is a major negative regulator of NRF2 stability ([@r40]). Kras-CL and Kras^IKKαL^ cells expressed similar amounts of KEAP1, however ([Fig. S6*A*](#d35e591){ref-type="supplementary-material"}). Expression of Nrf2 mRNA was lower in *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs than in *Kras*^*G12D*^ lungs ([Fig. 6*C*](#fig06){ref-type="fig"}). Knockdown of IKKα attenuated NRF2 expression, and reintroduction of IKKα rescued NRF2 expression ([Fig. S6*B*](#d35e591){ref-type="supplementary-material"}), suggesting that IKKα regulates *Nrf2* gene transcription.

![IKKα regulates NRF2 expression in an epigenetic manner. (*A*) Treatment with NAC (10 mM) inhibits DCF (ROS) levels in Kras^IKKαL^ cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*B*) Treatment with NAC (10 g/L) inhibits the development of lung tumors generated by Kras^IKKαL^ cells in WT mice. Control mice, *n* = 4; NAC-treated mice, *n* = 5. Data represent mean ± SD. \*\**P* \< 0.01, Student's *t* test. (*C*) RT-PCR analysis of Nrf2 mRNA levels in four WT, six *Kras*^*G12D*^, and 10 *Kras*^*G12D*^*;Ikkα*^∆*Lu*^ lungs. Data are analyzed by Student's *t* test. \**P* \< 0.05; \*\*\**P* \< 0.001. (*D*) RT-PCR analysis of Nrf2 mRNA in Kras-CL and Kras^IKKαL^ cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\**P* \< 0.01, Student's *t* test. (*E*) RT-PCR analysis of Nrf2 mRNA expression in Kras^IKKαL^ cells following treatment with 5-azacytidine (5-Aza). Data represent mean ± SD (three repeats). \*\**P* \< 0.01, Student's *t* test. n.s., not significant. (*F*) ChIP analyses for binding of IKKα, trimethylated-H3K9 (H3K9me3), Suv39h1, or Dnmt3a to *Nrf2* promoter using antibodies against these proteins for immunoprecipitation, followed by PCR with *Nrf2* promoter (-P) primers. Data represent mean ± SD (three repeats). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001, Student's *t* test. (*G*) Knockdown of IKKα (Si-IKKα) or reintroduction of WT IKKα, IKKα-∆LZ, and IKKα-KA regulates Nrf2 expression in Kras-CL cells, as analyzed by RT-PCR. Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001; \*\**P* \< 0.01, Student's *t* test. n.s., not significant. (*H*) A working model for NRF2 regulation and the pathways in IKKα^+^Kras^G12D^ and IKKα^−^Kras^G12D^ ADC cells. Blue circle, trimethylation; white circle, no trimethylation; S39h1, Suv39h1; H3, histone H3; arrow, promotion; cross lines, inhibition; dashed line, no response; dashed arrow, discussed in [Fig. 7](#fig07){ref-type="fig"}.](pnas.1717520115fig06){#fig06}

Trimethylation at lysine 9 of histone H3 (H3-K9) represses gene expression by recruiting DNA methyltransferases, and trimethyltransferase Suv39h1 is required for H3-K9 trimethylation ([@r13], [@r41], [@r42]). We previously reported that IKKα interacts directly with H3 protein, which in turn shields chromatin-associated H3 from H3-K9 trimethylation by preventing Suv39h1 from accessing the *Stratifin* chromatin ([@r13]). Several CpG islands are present in the *Nrf2* promoter region. Nrf2 mRNA levels were significantly lower in Kras^IKKαL^ cells than in Kras-CL cells ([Fig. 6*D*](#fig06){ref-type="fig"}). Treatment with 5-azacytidine, a DNA methyltransferase inhibitor, increased Nrf2 mRNA levels in Kras^IKKαL^ cells ([Fig. 6*E*](#fig06){ref-type="fig"}), suggesting that IKKα modulates the *Nrf2* promoter activity in an epigenetic manner.

Using ChIP assays, we found IKKα to be associated with the *Nrf2* promoter in Kras-CL cells ([Fig. 6*F*](#fig06){ref-type="fig"} and [Fig. S6*C*](#d35e591){ref-type="supplementary-material"}). With the loss of IKKα from the *Nrf2* promoter in Kras^IKKαL^ cells, increased levels of trimethylated-H3-K9, Suv39h1, and Dnmt3a were found at the *Nrf2* promoter compared with Kras-CL cells ([Fig. 6*F*](#fig06){ref-type="fig"} and [Fig. S6*C*](#d35e591){ref-type="supplementary-material"}). Reintroducing WT IKKα or IKKα-KA, but not IKKα-∆LZ, formed the complex with *Nrf2* promoter in Kras^IKKαL^ cells ([Fig. S6*D*](#d35e591){ref-type="supplementary-material"}). Consistently, silencing IKKα decreased Nrf2 expression in Kras-CL cells, and reintroducing WT IKKα or IKKα-KA, but not IKKα-∆LZ, increased Nrf2 expression in IKKα-deficient Kras-CL cells ([Fig. 6*G*](#fig06){ref-type="fig"}). These results suggest that IKKα suppresses H3-K9 trimethylation on the *Nrf2* promoter, thereby increasing its transcription. In contrast, IKKα loss elevates H3-K9 trimethylation on the *Nrf2* promoter, inhibiting NRF2 expression ([Fig. 6*H*](#fig06){ref-type="fig"} and [Fig. S6*E*](#d35e591){ref-type="supplementary-material"}).

To elucidate how IKKα expression is down-regulated in Kras^IKKαL^ cells, we sequenced full-length IKKα cDNA and identified a missense mutation at nucleotide 2054 (amino acid 685) in Kras^IKKαL^ cells, Kras-CL cells, and Kras^G12D^-induced ADCs ([Fig. S6*F*](#d35e591){ref-type="supplementary-material"}). Interestingly, Kras^IKKαL^ cells exhibited many additional *Ikkα* mutations surrounding the nucleotide 2054 genetic lesion, suggesting that these mutations confer a growth advantage, possibly by destabilizing the IKKα protein. Accordingly, IKKα immunoprecipitation from Kras-CL and Kras^IKKαL^ cells, followed by IB analysis with an anti-ubiquitin antibody, showed more ubiquitinated IKKα in Kras^IKKαL^ cells compared with Kras-CL cells ([Fig. S6*G*](#d35e591){ref-type="supplementary-material"}, *Top*). Treatment with MG132, a proteasome inhibitor, elevated IKKα and NRF2 levels in Kras^IKKαL^ cells ([Fig. S6*G*](#d35e591){ref-type="supplementary-material"}, *Bottom*), suggesting that tumor-associated mutations promote proteasomal degradation of IKKα. We previously detected the same *Ikkα* mutations and deletions in the C-terminal region of IKKα in skin SCCs derived from carcinogen-treated *Ikkα*^*+/−*^ and WT mice ([@r13], [@r15], [@r26]). These mutations impaired the IKKα activity that controls the G2/M cell cycle checkpoint in response to DNA damage and keratinocyte growth. Thus, the DNA encoding the IKKα C-terminal region behaves like a mutational "hot spot" in different types of cancers.

A ROS-Mediated NRF2-NQO1 Pathway Leads to the Induction of p53/p21 and Cell Senescence, and IKKα Inactivation Reverses This Pathway. {#s8}
------------------------------------------------------------------------------------------------------------------------------------

Reduction of NQO1, an NRF2 target, results in p53 degradation independent of MDM2 ([@r43], [@r44]), suggesting that along with antioxidative activity, the ROS-mediated NRF2-NQO1 pathway may prevent tumor progression by up-regulating p53, p21, and cell senescence ([@r30]). We hypothesized that reduced IKKα down-regulates NRF2 and NQO1 expression, which attenuates p53 and p21 expression and cell senescence. Indeed, Kras^IKKαL^ cells expressed reduced IKKα, NRF2, NQO1, p53, and p21 and showed attenuated cell senescence compared with Kras-CL cells ([Fig. 7 *A*](#fig07){ref-type="fig"}, *Left* and [*B*](#fig07){ref-type="fig"}). Silencing of IKKα repressed NRF2, NQO1, p53, and p21 expression and attenuated cell senescence in Kras-CL and A549 cells ([Fig. 7 *A*](#fig07){ref-type="fig"}, *Center* and [*C*](#fig07){ref-type="fig"} and [Fig. S7 *A* and *B*](#d35e591){ref-type="supplementary-material"}). In addition, silencing of NRF2 or NQO1 repressed NQO1, p53, and p21 expression and attenuated cell senescence in Kras-CL cells ([Fig. 7 *A*](#fig07){ref-type="fig"}, *Right*, [*D* and *E*](#fig07){ref-type="fig"} and [Fig. S7*C*](#d35e591){ref-type="supplementary-material"}). These results suggest that IKKα reduction blocks cell cycle arrest by decreasing NRF2, NQO1, and p21 expression. Importantly, silencing of IKKα, NRF2, or NQO1 in Kras-CL cells promoted tumor growth compared with the control when these cells were injected s.c. into nude mice ([Fig. 7 *F--H*](#fig07){ref-type="fig"}).

![An antagonizing relationship between accumulating ROS pathways and senescence. (*A*) IB analysis of IKKα, NRF2, NQO1, p53, p21, and MDM2 expression in Kras-CL and Kras^IKKαL^ cells (*Left*), as well as Kras-CL cells treated with Si-Control, Si-IKKα (*Center*), or Si-NQO1 (*Right*). β-actin served as a protein-loading control. (*B*) SA-β-gal--positive cells in Kras-CL and Kras^IKKαL^ cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*C*) The effect of IKKα knockdown on SA-β-gal levels in Kras-CL cells (*Left*) and A459 cells (*Right*) (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*D*) The effect of NRF2 knockdown on SA-β-gal levels in Kras-CL cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*E*) The effect of NQO1 knockdown on SA-β-gal levels in Kras-CL cells (*n* = 3/group). Data represent mean ± SD (three repeats). \*\*\**P* \< 0.001, Student's *t* test. (*F*) Appearance (*Left*) and weight (*Right*) of tumors in nude mice receiving s.c. injections of Si-control or Si-IKKα--transfected Kras-CL cells for 3 wk (*n* = 10 tumors from 5 mice/group). Data represent mean ± SD. \*\**P* \< 0.01, Student's *t* test. (*G*) Appearance (*Left*) and weight (*Right*) of tumors in nude mice receiving s.c. injections of Si-control or Si-NRF2--transfected Kras-CL cells for 3 wk (*n* = 10 tumors from 5 mice/group). Data represent mean ± SD. \*\**P* \< 0.01, Student's *t* test. (*H*) Appearance (*Top*) and weight (*Bottom*) of tumors in nude mice receiving s.c. injections of Si-control or Si-NQO1 transfected Kras-CL cells for 3 wk (*n* = 9 tumors from 5 mice/group). Data represent mean ± SD. \**P* \< 0.05, Student's *t* test. (*I*) IB analysis of p53 and p21 expression in Kras-CL and Kras^IKKαL^ cells treated with NAC or apocynin (Apocy). Cont, untreated cells. β-actin served as a protein-loading control. (*J*) A working model for regulation of NOX2 or NRF2, their pathways, and biological consequences, regulated by IKKα in IKKα^+^Kras^G12D^ and IKKα^−^Kras^G12D^ ADC cells. Blue circle, trimethylation; white circle, no trimethylation; S39h1, Suv39h1; H3, histone H3; arrow, promotion or forward/maintaining; cross lines, inhibition; dashed line, no response.](pnas.1717520115fig07){#fig07}

To demonstrate links among IKKα action, ROS, and ROS-mediated cell senescence, we examined the effect of NAC and apocynin on cell senescence (p53/p21) in Kras^IKKαL^ and Kras-CL cells ([Fig. 7*I*](#fig07){ref-type="fig"}). Indeed, treatment with NAC or apocynin induced p53/p21 expression in Kras^IKKαL^ cells. This induction was stronger in Kras^IKKαL^ cells than in Kras-CL cells ([Fig. 7*I*](#fig07){ref-type="fig"}). Taken together, these findings show that IKKα ablation not only elevates NOX2 expression, but also blocks the induction of NRF2 and NQO1, resulting in accumulated ROS and attenuated cell senescence, both of which promote lung tumor development ([Fig. 7*J*](#fig07){ref-type="fig"}).

Furthermore, we examined NF-κB activity in Kras-CL and Kras^IKKαL^ cells following TNFα treatment, and found that NF-κB activity was not decreased in Kras^IKKαL^ cells compared with Kras-CL cells ([Fig. S7*D*](#d35e591){ref-type="supplementary-material"}). However, relative to Kras-CL, Kras^IKKαL^ cells showed increased expression of the regulators for stem cell properties, mitogenic activity, and inflammation and reduced expression of the regulators for apoptosis and antioxidant/detoxification functions, as analyzed by a microarray assay (GSE84163; [Fig. S7*E*](#d35e591){ref-type="supplementary-material"}). Among these alterations, IKKα down-regulates Fgf13, Adam12, and Egfr ([@r14], [@r15]) and ROS elevate Jak2, Egfr, and Notch1 expression ([@r45][@r46]--[@r47]). These changes may also contribute to the enhanced tumorigenic potential of Kras^IKKαL^ cells compared with Kras-CL cells.

Discussion {#s9}
==========

Here we demonstrate that lung-specific IKKα deletion promotes Kras^G12D^-mediated lung ADC development in association with elevated NOX2, down-regulated NRF2, accumulated ROS, and attenuated cell senescence. Pharmacologic inhibition of NOX or ROS attenuates lung ADC development in *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ mice. These results define a previously undescribed role of IKKα, in which dual IKKα-NOX2 and IKKα-NRF2 pathways control ROS homeostasis and proliferation/survival that regulate Kras^G12D^-mediated lung ADC growth. Importantly, a fraction of human lung ADCs harbor *CHUK* locus mutations and deletions or express reduced IKKα, some of which coexpress activated KRAS. During malignancy development, the activation of oncogenes is a ubiquitous phenomenon. Human lung ADCs express different oncogenes that induce mitogenic stress and ROS ([@r29]). Therefore, the mechanism identified in this study may apply in those *CHUK*-deficient human ADCs that do not carry *KRAS* alterations. Furthermore, *KRAS* mutations frequently occur in human pancreatic and colon cancers (cBioPortal). *CHUK* mutations and hemizygous deletions are also found in these patients, suggesting that IKKα inactivation or reduction may promote *KRAS* mutation-involved pancreatic and colon cancer development through a mechanism provided in this study.

FVB [*l*]{.smallcaps}*-Ikkα*^*KA/KA*^ mice develop spontaneous lung SCCs, in which no activating *Kras* mutations are detected, but not ADCs ([@r5]). [*l*]{.smallcaps}*-Ikkα*^*KA/KA*^ mice develop systemic inflammation, marked pulmonary macrophage infiltration, and reduced epithelial cell IKKα levels before lung SCC formation. Restoration of IKKα in K5-expressing lung epithelial cells or depleting macrophages prevents lung SCC development. In this study, we detected lung ADCs, but not SCCs, in *Kras*^*G12D*^, *Ikkα*^Δ*LU*^, and *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ mice. These mice have a WT background before Ad.Cre treatment. Furthermore, *Kras*^*G12D*^*;Ikkα*^*KA/KA*^ mice only developed lung ADCs. Notably, activating *KRAS* mutations are detected in ∼35% and 5% of human lung ADCs and SCCs, respectively ([@r1], [@r2]), suggesting that activated Kras may predominantly induce ADCs in the lung, and that inflammatory conditions may also determine the formation of lung cancer, either ADC or SCC ([@r4]). The detailed mechanism remains to be revealed. Moreover, lung-specific *Ikkα* ablation induced spontaneous lung ADCs. Reintroduction of IKKα inhibited Kras^IKKαL^ cell-generated tumor growth, and silencing of IKKα promoted Kras-CL cell-generated tumor growth. Hence, the epithelial-intrinsic IKKα is critical for suppressing lung ADC development.

Down-regulation of NF-κB can cause apoptosis of Kras^G12D^ ADC cells expressing reduced p53 ([@r17], [@r18]). Here, we showed that *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ and Kras^G12D^ ADCs expressed comparable amounts of nuclear NF-κB proteins, although p53 expression was lower in *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ ADCs than in *Kas*^*G12D*^ ADCs, suggesting that a basal NF-κB activity is sufficient for maintaining tumor cell survival. Furthermore, *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ ADCs showed increased proliferating cells and reduced p53/p21/senescence. NQO1 has been shown to stabilize the p53 protein independent of MDM2, while reduced NQO1 destabilizes p53 ([@r43], [@r44]). We found that IKKα deletion decreased expression of NRF2 and NQO1, which led to reduced p53/p21 and cell senescence in lung cancer cells, suggesting that IKKα is required to maintain NRF2, NQO1, and p53/p21 pathways for establishment of a barrier that antagonizes tumor progression.

On the other hand, silencing of IKKα was found to down-regulate NRF2 and NQO1 expression, resulting in reduced p53/p21 expression and cell senescence. Therefore, a reduction in IKKα changes the antitumorigenic effect of Kras-induced ROS to a protumorigenic effect that enhances Kras-induced ADC progression. Although it has been reported that NRF2 deletion alone promotes the Kras^G12D^-mediated early ADCs and inhibits the advanced Kras^G12D^-mediated ADCs ([@r23], [@r48]), in this study, along with reduced NRF2, IKKα deletion also promoted NOX2 expression, leading to further ROS accumulation and oxidative damage. Most likely, the ROS scavenging system induced by NRF2 becomes more crucial for reducing oxidative damage in *Kras*^*G12D*^*;Ikkα*^Δ*LU*^ mice than in *Kras*^*G12D*^ mice. Overall, IKKα provides a protective role that suppresses excessive ROS and also ensures a pathway for ROS-induced antitumorigenic activity, thereby preventing ADC initiation and progression.

Materials and Methods {#s10}
=====================

All mice used in this study were cared for in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the National Institutes of Health. All animal experiments (protocols 14--051 and 14--052) were approved by the IACUC. *Ikkα*^*f/f*^, *Ikkα*^*KA/KA*^, and *Ikkα*^*+/−*^ mice ([@r12], [@r13], [@r15]) and *Kras*^*G12D*^ mice (stock no. 008179; The Jackson Laboratory) were on a C57BL/6 background. Athymic nude mice were obtained from Charles River Laboratories \[BALB/c; Crl:NU(NCr)-Foxn1^nu^\]. Human lung adenocarcinomas were obtained from Dr. David Schrump, Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute and from Sun Yat-Sen University Cancer Center, Guangzhou, China. All human samples used in this study were approved by the National Institutes of Health Internal Review Board (protocol 06-C-0014) and by the Ethics Committee and Institutional Review Board of Sun Yat-Sen University Cancer Center (YB2017-023), and informed consent was been obtained from all patients.
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